PeptImmune Peps Up with $8 Million Financing
Robert Buderi1/18/08
Cambridge, MA-based PeptImmune, a Genzyme biotech spinoff that’s developing therapies for treatment of obesity, multiple sclerosis, rheumatoid arthritis, and other chronic autoimmune or inflammatory disorders, has taken in $8.2 million under the first tranche of a Series D round. The financing was led by New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Investors, and Silicon Valley Bank Capital, among others, according to the press release. Peptimmune said it expects to close another stage of the round in the second quarter of 2008.
Bob is Xconomy's founder and editor in chief. You can e-mail him at bbuderi@xconomy.com, call him at 617.500.5926, or follow him on Twitter at http://twitter.com/bbuderi.
